BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 10474189)

  • 21. Does dapsone resistance really matter in the MDT era?
    Ji B
    Int J Lepr Other Mycobact Dis; 2001 Mar; 69(1):54-5. PubMed ID: 11480322
    [No Abstract]   [Full Text] [Related]  

  • 22. Inhibitory effect of natural compounds on Dihydropteroate synthase of
    Khan M; Khan S; Bushara NZA; Ali R; Tabassum Z; Ishrat R; Marouf HA; Sherwani S; Mirza S; Haque S
    J Biomol Struct Dyn; 2023; 41(23):13857-13872. PubMed ID: 37070201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations in genes related to drug resistance in Mycobacterium leprae isolates from leprosy patients in Korea.
    You EY; Kang TJ; Kim SK; Lee SB; Chae GT
    J Infect; 2005 Jan; 50(1):6-11. PubMed ID: 15603834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The frequency of drug resistance mutations in Mycobacterium leprae isolates in untreated and relapsed leprosy patients from Myanmar, Indonesia and the Philippines.
    Matsuoka M; Budiawan T; Aye KS; Kyaw K; Tan EV; Cruz ED; Gelber R; Saunderson P; Balagon V; Pannikar V
    Lepr Rev; 2007 Dec; 78(4):343-52. PubMed ID: 18309708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multidrug resistant Mycobacterium leprae from patients with leprosy.
    Maeda S; Matsuoka M; Nakata N; Kai M; Maeda Y; Hashimoto K; Kimura H; Kobayashi K; Kashiwabara Y
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3635-9. PubMed ID: 11709358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin.
    Matsuoka M; Kashiwabara Y; Namisato M
    Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):452-5. PubMed ID: 11332288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug resistant leprosy--a comparison between proven dapsone and proven thiambutosine resistance.
    Waters MF; Pearson JM; Rees RJ
    Int J Lepr Other Mycobact Dis; 1976; 44(1-2):152-3. PubMed ID: 776850
    [No Abstract]   [Full Text] [Related]  

  • 28. In vivo activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with dapsone, against Mycobacterium leprae.
    Dhople AM
    Int J Antimicrob Agents; 2002 Jan; 19(1):71-4. PubMed ID: 11814771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dormancy, drug resistance or dependency; some thoughts to ponder.
    Shetty VP; Mistry NF; Uplekar MW; Antia NH; Pai VV; Ganapati R
    Int J Lepr Other Mycobact Dis; 1996 Dec; 64(4):455-7. PubMed ID: 9030116
    [No Abstract]   [Full Text] [Related]  

  • 30. Possible mode of emergence for drug-resistant leprosy is revealed by an analysis of samples from Mexico.
    Matsuoka M; Suzuki Y; Garcia IE; Fafutis-Morris M; Vargas-González A; Carreño-Martinez C; Fukushima Y; Nakajima C
    Jpn J Infect Dis; 2010 Nov; 63(6):412-6. PubMed ID: 21099091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cloning and expression of Mycobacterium tuberculosis and Mycobacterium leprae dihydropteroate synthase in Escherichia coli.
    Nopponpunth V; Sirawaraporn W; Greene PJ; Santi DV
    J Bacteriol; 1999 Nov; 181(21):6814-21. PubMed ID: 10542185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Drug resistance of Mycobacterium leprae].
    Pattyn SR
    Acta Leprol; 1986; 4(3):279-87. PubMed ID: 3551466
    [No Abstract]   [Full Text] [Related]  

  • 33. [Novel method for simple detection of mutations conferring drug resistance in Mycobacterium leprae, based on a DNA microarray, and its applicability in developing countries].
    Matsuoka M; Suzuki Y; Makino M
    Nihon Hansenbyo Gakkai Zasshi; 2010 Sep; 79(3):257-61. PubMed ID: 20857655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multidrug-resistance to dapsone, rifampicin, and ofloxacin in Mycobacterium leprae.
    Cambau E; Perani E; Guillemin I; Jamet P; Ji B
    Lancet; 1997 Jan; 349(9045):103-4. PubMed ID: 8996430
    [No Abstract]   [Full Text] [Related]  

  • 35. Drug resistant-Mycobacterium leprae--results of mouse footpad studies from a laboratory in south India.
    Ebenezer GJ; Norman G; Joseph GA; Daniel S; Job CK
    Indian J Lepr; 2002; 74(4):301-12. PubMed ID: 12624978
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dapsone drug resistance in the MDT era.
    Roche PW; Neupane KD; Failbus SS; Butlin CR
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):323-5. PubMed ID: 11221097
    [No Abstract]   [Full Text] [Related]  

  • 37. Drug resistance in leprosy: lessons from past and future perspective.
    Gupta UD; Katoch VM
    Indian J Lepr; 1999; 71(4):451-63. PubMed ID: 10804973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is drug-resistant Mycobacterium leprae a real cause for concern?: First approach to molecular monitoring of multibacillary Colombian patients with and without previous leprosy treatment.
    Guerrero MI; Colorado CL; Torres JF; León CI
    Biomedica; 2014 Apr; 34 Suppl 1():137-47. PubMed ID: 24968045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug resistance in patients with leprosy in the United States.
    Williams DL; Lewis C; Sandoval FG; Robbins N; Keas S; Gillis TP; Scollard DM
    Clin Infect Dis; 2014 Jan; 58(1):72-3. PubMed ID: 24065328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with brodimoprim and dapsone, against Mycobacterium leprae.
    Dhople AM
    Int J Antimicrob Agents; 1999 Aug; 12(4):319-23. PubMed ID: 10493608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.